Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

At Reuters Pharma USA in Philadelphia, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...